CXCL8 and juvenile idiopathic arthritis: Targeting CD14 Mono to inhibit IL-6 and IL-8 might offer therapeutic potential for treating HLA-B27- JIA, especially considering the stronger IL-6 and IL-8 production observed in this subtype.